文献速递区域麻醉与超声术前评估与围术期医学

胸肌II筋膜阻滞在乳腺癌手术中的镇痛效果:系统综述与荟萃分析

Pectoralis-II Myofascial Block and Analgesia in Breast Cancer Surgery: A Systematic Review and Meta-analysis.
PubMed 文献 · Anesthesiology · 2019-01-01

结果显示,与全身镇痛相比,胸肌II阻滞显著降低24小时吗啡消耗量(加权均数差-30.5 mg,95%CI -42.2至-18.8,P<0.00001)和静息痛曲线下面积;与椎旁阻滞相比,胸肌II阻滞在24小时吗啡消耗量和静息痛曲线下面积上均不劣于椎旁阻滞。证据支持将胸肌II阻滞纳入多模式镇痛,并作为椎旁阻滞的替代方案。

要点

  • 胸肌II阻滞较单纯全身镇痛减少24小时吗啡消耗至少30.0 mg。
  • 胸肌II阻滞在24小时吗啡消耗和静息痛上不劣于椎旁阻滞。
  • 两组阿片相关副作用及其他结局无差异。

核心结论

  • 胸肌II阻滞较全身镇痛减少术后24小时疼痛强度和吗啡消耗。
  • 胸肌II阻滞的镇痛效果不劣于椎旁阻滞。
  • 证据支持将胸肌II阻滞纳入多模式镇痛并作为椎旁阻滞替代。

研究设计与样本

  • 系统综述与荟萃分析,检索比较胸肌II阻滞与全身镇痛或椎旁阻滞的乳腺癌手术试验。
  • 采用随机效应模型合并结果。

主要发现

  • 与全身镇痛相比,胸肌II阻滞24小时吗啡消耗加权均数差为-30.5 mg(95%CI -42.2至-18.8,P<0.00001)。
  • 与全身镇痛相比,胸肌II阻滞24小时以上静息痛曲线下面积差为-4.7 cm·h(95%CI -5.1至-4.2),每次测量差为-1.2 cm(95%CI -1.3至-1.1)。
  • 与椎旁阻滞相比,胸肌II阻滞24小时吗啡消耗无统计学差异,24小时以上静息痛曲线下面积无临床差异。
  • 阿片相关副作用及其他结局无差异。

关键数值与推荐

  • 共同主要结局为术后口服吗啡消耗量和24小时以上合并静息痛评分曲线下面积差异。
  • 与全身镇痛相比,胸肌II阻滞24小时吗啡消耗减少至少30.0 mg(加权均数差-30.5 mg,95%CI -42.2至-18.8,P<0.00001)。
  • 与椎旁阻滞相比,胸肌II阻滞24小时吗啡消耗无统计学差异。

临床怎么用

  • 可将胸肌II阻滞纳入乳腺癌手术多模式镇痛方案。
  • 胸肌II阻滞可作为椎旁阻滞的替代方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thoracic paravertebral block is the preferred regional anesthetic technique for breast cancer surgery, but concerns over its invasiveness and risks have prompted search for alternatives. Pectoralis-II block is a promising analgesic technique and potential alternative to paravertebral block, but evidence of its absolute and relative effectiveness versus systemic analgesia (Control) and paravertebral block, respectively, is conflicting. This meta-analysis evaluates the analgesic effectiveness of Pectoralis-II versus Control and paravertebral block for breast cancer surgery. METHODS: Databases were searched for breast cancer surgery trials comparing Pectoralis-II with Control or paravertebral block. Postoperative oral morphine consumption and difference in area under curve for pooled rest pain scores more than 24 h were designated as coprimary outcomes. Opioid-related side effects, effects on long-term outcomes, such as chronic pain and opioid dependence, were also examined. Results were pooled using random-effects modeling. RESULTS: Fourteen randomized trials (887 patients) were analyzed. Compared with Control, Pectoralis-II provided clinically important reductions in 24-h morphine consumption (at least 30.0 mg), by a weighted mean difference [95% CI] of -30.5 mg [-42.2, -18.8] (P < 0.00001), and in rest pain area under the curve more than 24 h, by -4.7cm · h [-5.1, -4.2] or -1.2cm [-1.3, -1.1] per measurement. Compared with paravertebral block, Pectoralis-II was not statistically worse (not different) for 24-h morphine consumption, and not clinically worse for rest pain area under curve more than 24 h. No differences were observed in opioid-related side effects or any other outcomes. CONCLUSIONS: We found that Pectoralis-II reduces pain intensity and morphine consumption during the first 24 h postoperatively when compared with systemic analgesia alone; and it also offers analgesic benefits noninferior to those of paravertebral block after breast cancer surgery. Evidence supports incorporating Pectoralis-II into multimodal analgesia and also using it as a paravertebral block alternative in this population.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Hussain N, Brull R, McCartney CJL, et al. Pectoralis-II Myofascial Block and Analgesia in Breast Cancer Surgery: A Systematic Review and Meta-analysis. Anesthesiology. 2019. PMID: 31408448. doi:10.1097/ALN.0000000000002822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。